APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenzavirus B Infection Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Influenzavirus B Infection Drug Industry Growth and Trends Forecast to 2032

Report ID 174002720119 December 2025124 pages

Choose your research edition.

Industry ResearchInfluenzavirus B Infection Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenzavirus B Infection Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Influenzavirus B Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenzavirus B Infection Drug Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Influenzavirus B Infection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Influenzavirus B Infection Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Influenzavirus B Infection Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Influenzavirus B Infection Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Influenzavirus B Infection Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Influenzavirus B Infection Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Influenzavirus B Infection Drug Market by Company

Sanofi

AbbVie Inc

Vectura Group Plc

Vaxart Inc

TSRL Inc

SK Chemicals Co Ltd

Shionogi & Co Ltd

Sanofi Pasteur SA

Romark Laboratories LC

Park Active Molecules

Novavax Inc

Mucosis BV

MedImmune LLC

Medicago Inc

Kineta Inc

Inovio Pharmaceuticals Inc

Green Cross Corp

GlaxoSmithKline Plc

Fujifilm Holdings Corporation

Daiichi Sankyo Company Ltd

ContraFect Corp

Cadila Healthcare Ltd

BioCryst Pharmaceuticals Inc

Aphios Corp

Amarillo Biosciences Inc

Altravax Inc

Adimmune Corp

Influenzavirus B Infection Drug Segment by Type

KIN-1400

GC-3106A

CF-403

APP-309

Others

Influenzavirus B Infection Drug Segment by Application

Clinic

Hospital

Others

Influenzavirus B Infection Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of KIN-1400 Table 2. Major Company of GC-3106A Table 3. Major Company of CF-403 Table 4. Major Company of APP-309 Table 5. Major Company of Others Table 6. Global Influenzavirus B Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Influenzavirus B Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Influenzavirus B Infection Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Influenzavirus B Infection Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Influenzavirus B Infection Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Influenzavirus B Infection Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Influenzavirus B Infection Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Influenzavirus B Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Influenzavirus B Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Influenzavirus B Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Influenzavirus B Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Influenzavirus B Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Influenzavirus B Infection Drug Industry Trends Table 28. Influenzavirus B Infection Drug Industry Drivers Table 29. Influenzavirus B Infection Drug Industry Opportunities and Challenges Table 30. Influenzavirus B Infection Drug Industry Restraints Table 31. Global Influenzavirus B Infection Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Influenzavirus B Infection Drug Revenue Market Share by Company (2021-2026) Table 33. Global Influenzavirus B Infection Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Influenzavirus B Infection Drug Sales Share by Company (2021-2026) Table 35. Global Influenzavirus B Infection Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Influenzavirus B Infection Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Influenzavirus B Infection Drug Major Company Production Sites and Headquarters Table 38. Global Influenzavirus B Infection Drug Company, Product Type & Application Table 39. Global Influenzavirus B Infection Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Influenzavirus B Infection Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Influenzavirus B Infection Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Influenzavirus B Infection Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Influenzavirus B Infection Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Influenzavirus B Infection Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Influenzavirus B Infection Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Influenzavirus B Infection Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Influenzavirus B Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Influenzavirus B Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Influenzavirus B Infection Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Influenzavirus B Infection Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Influenzavirus B Infection Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Influenzavirus B Infection Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Influenzavirus B Infection Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Influenzavirus B Infection Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Influenzavirus B Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Influenzavirus B Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Influenzavirus B Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Influenzavirus B Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Influenzavirus B Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sanofi Influenzavirus B Infection Drug Product Portfolio Table 78. Sanofi Recent Development Table 79. AbbVie Inc Company Information Table 80. AbbVie Inc Business Overview Table 81. AbbVie Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AbbVie Inc Influenzavirus B Infection Drug Product Portfolio Table 83. AbbVie Inc Recent Development Table 84. Vectura Group Plc Company Information Table 85. Vectura Group Plc Business Overview Table 86. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio Table 88. Vectura Group Plc Recent Development Table 89. Vaxart Inc Company Information Table 90. Vaxart Inc Business Overview Table 91. Vaxart Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Vaxart Inc Influenzavirus B Infection Drug Product Portfolio Table 93. Vaxart Inc Recent Development Table 94. TSRL Inc Company Information Table 95. TSRL Inc Business Overview Table 96. TSRL Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. TSRL Inc Influenzavirus B Infection Drug Product Portfolio Table 98. TSRL Inc Recent Development Table 99. SK Chemicals Co Ltd Company Information Table 100. SK Chemicals Co Ltd Business Overview Table 101. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 103. SK Chemicals Co Ltd Recent Development Table 104. Shionogi & Co Ltd Company Information Table 105. Shionogi & Co Ltd Business Overview Table 106. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 108. Shionogi & Co Ltd Recent Development Table 109. Sanofi Pasteur SA Company Information Table 110. Sanofi Pasteur SA Business Overview Table 111. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio Table 113. Sanofi Pasteur SA Recent Development Table 114. Romark Laboratories LC Company Information Table 115. Romark Laboratories LC Business Overview Table 116. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio Table 118. Romark Laboratories LC Recent Development Table 119. Park Active Molecules Company Information Table 120. Park Active Molecules Business Overview Table 121. Park Active Molecules Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Park Active Molecules Influenzavirus B Infection Drug Product Portfolio Table 123. Park Active Molecules Recent Development Table 124. Novavax Inc Company Information Table 125. Novavax Inc Business Overview Table 126. Novavax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Novavax Inc Influenzavirus B Infection Drug Product Portfolio Table 128. Novavax Inc Recent Development Table 129. Mucosis BV Company Information Table 130. Mucosis BV Business Overview Table 131. Mucosis BV Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Mucosis BV Influenzavirus B Infection Drug Product Portfolio Table 133. Mucosis BV Recent Development Table 134. MedImmune LLC Company Information Table 135. MedImmune LLC Business Overview Table 136. MedImmune LLC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. MedImmune LLC Influenzavirus B Infection Drug Product Portfolio Table 138. MedImmune LLC Recent Development Table 139. Medicago Inc Company Information Table 140. Medicago Inc Business Overview Table 141. Medicago Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Medicago Inc Influenzavirus B Infection Drug Product Portfolio Table 143. Medicago Inc Recent Development Table 144. Kineta Inc Company Information Table 145. Kineta Inc Business Overview Table 146. Kineta Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Kineta Inc Influenzavirus B Infection Drug Product Portfolio Table 148. Kineta Inc Recent Development Table 149. Inovio Pharmaceuticals Inc Company Information Table 150. Inovio Pharmaceuticals Inc Business Overview Table 151. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 153. Inovio Pharmaceuticals Inc Recent Development Table 154. Green Cross Corp Company Information Table 155. Green Cross Corp Business Overview Table 156. Green Cross Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Green Cross Corp Influenzavirus B Infection Drug Product Portfolio Table 158. Green Cross Corp Recent Development Table 159. GlaxoSmithKline Plc Company Information Table 160. GlaxoSmithKline Plc Business Overview Table 161. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio Table 163. GlaxoSmithKline Plc Recent Development Table 164. Fujifilm Holdings Corporation Company Information Table 165. Fujifilm Holdings Corporation Business Overview Table 166. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio Table 168. Fujifilm Holdings Corporation Recent Development Table 169. Daiichi Sankyo Company Ltd Company Information Table 170. Daiichi Sankyo Company Ltd Business Overview Table 171. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio Table 173. Daiichi Sankyo Company Ltd Recent Development Table 174. ContraFect Corp Company Information Table 175. ContraFect Corp Business Overview Table 176. ContraFect Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. ContraFect Corp Influenzavirus B Infection Drug Product Portfolio Table 178. ContraFect Corp Recent Development Table 179. Cadila Healthcare Ltd Company Information Table 180. Cadila Healthcare Ltd Business Overview Table 181. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio Table 183. Cadila Healthcare Ltd Recent Development Table 184. BioCryst Pharmaceuticals Inc Company Information Table 185. BioCryst Pharmaceuticals Inc Business Overview Table 186. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 188. BioCryst Pharmaceuticals Inc Recent Development Table 189. Aphios Corp Company Information Table 190. Aphios Corp Business Overview Table 191. Aphios Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 192. Aphios Corp Influenzavirus B Infection Drug Product Portfolio Table 193. Aphios Corp Recent Development Table 194. Amarillo Biosciences Inc Company Information Table 195. Amarillo Biosciences Inc Business Overview Table 196. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 197. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio Table 198. Amarillo Biosciences Inc Recent Development Table 199. Altravax Inc Company Information Table 200. Altravax Inc Business Overview Table 201. Altravax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 202. Altravax Inc Influenzavirus B Infection Drug Product Portfolio Table 203. Altravax Inc Recent Development Table 204. Adimmune Corp Company Information Table 205. Adimmune Corp Business Overview Table 206. Adimmune Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 207. Adimmune Corp Influenzavirus B Infection Drug Product Portfolio Table 208. Adimmune Corp Recent Development Table 209. North America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 210. North America Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 211. North America Influenzavirus B Infection Drug Sales Market Share by Country (2021-2026) Table 212. North America Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032) & (K Units) Table 213. North America Influenzavirus B Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 214. North America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 215. North America Influenzavirus B Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 216. North America Influenzavirus B Infection Drug Market Share by Country (2021-2026) Table 217. North America Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 218. North America Influenzavirus B Infection Drug Market Share Forecast by Country (2027-2032) Table 219. Europe Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 220. Europe Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 221. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2021-2026) Table 222. Europe Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032) & (K Units) Table 223. Europe Influenzavirus B Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 224. Europe Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 225. Europe Influenzavirus B Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 226. Europe Influenzavirus B Infection Drug Market Share by Country (2021-2026) Table 227. Europe Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 228. Europe Influenzavirus B Infection Drug Market Share Forecast by Country (2027-2032) Table 229. Asia-Pacific Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 230. Asia-Pacific Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 231. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share by Country (2021-2026) Table 232. Asia-Pacific Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032) & (K Units) Table 233. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 234. Asia-Pacific Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 235. Asia-Pacific Influenzavirus B Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 236. Asia-Pacific Influenzavirus B Infection Drug Market Share by Country (2021-2026) Table 237. Asia-Pacific Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 238. Asia-Pacific Influenzavirus B Infection Drug Market Share Forecast by Country (2027-2032) Table 239. Latin America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 240. Latin America Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 241. Latin America Influenzavirus B Infection Drug Sales Market Share by Country (2021-2026) Table 242. Latin America Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032) & (K Units) Table 243. Latin America Influenzavirus B Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 244. Latin America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 245. Latin America Influenzavirus B Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 246. Latin America Influenzavirus B Infection Drug Market Share by Country (2021-2026) Table 247. Latin America Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 248. Latin America Influenzavirus B Infection Drug Market Share Forecast by Country (2027-2032) Table 249. Middle East and Africa Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 250. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 251. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2021-2026) Table 252. Middle East and Africa Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032) & (K Units) Table 253. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 254. Middle East and Africa Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 255. Middle East and Africa Influenzavirus B Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 256. Middle East and Africa Influenzavirus B Infection Drug Market Share by Country (2021-2026) Table 257. Middle East and Africa Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 258. Middle East and Africa Influenzavirus B Infection Drug Market Share Forecast by Country (2027-2032) Table 259. Key Raw Materials Table 260. Raw Materials Key Suppliers Table 261. Influenzavirus B Infection Drug Distributors List Table 262. Influenzavirus B Infection Drug Customers List Table 263. Research Programs/Design for This Report Table 264. Authors List of This Report Table 265. Secondary Sources Table 266. Primary Sources List of Figures Figure 1. Influenzavirus B Infection Drug Image Figure 2. Global Influenzavirus B Infection Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenzavirus B Infection Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenzavirus B Infection Drug Sales (2021-2032) & (K Units) Figure 5. KIN-1400 Image Figure 6. Global KIN-1400 Sales YoY Growth (2021-2032) & (K Units) Figure 7. GC-3106A Image Figure 8. Global GC-3106A Sales YoY Growth (2021-2032) & (K Units) Figure 9. CF-403 Image Figure 10. Global CF-403 Sales YoY Growth (2021-2032) & (K Units) Figure 11. APP-309 Image Figure 12. Global APP-309 Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Influenzavirus B Infection Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Influenzavirus B Infection Drug Market Share by Type 2025 VS 2032 Figure 17. North America Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Influenzavirus B Infection Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Influenzavirus B Infection Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Influenzavirus B Infection Drug Market Share by Application 2025 VS 2032 Figure 37. North America Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Influenzavirus B Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Influenzavirus B Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Influenzavirus B Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Influenzavirus B Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Influenzavirus B Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Influenzavirus B Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Influenzavirus B Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Influenzavirus B Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Influenzavirus B Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Influenzavirus B Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Influenzavirus B Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Influenzavirus B Infection Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Influenzavirus B Infection Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • KIN-1400
  • GC-3106A
  • CF-403
  • APP-309
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sanofi
  • AbbVie Inc
  • Vectura Group Plc
  • Vaxart Inc
  • TSRL Inc
  • SK Chemicals Co Ltd
  • Shionogi & Co Ltd
  • Sanofi Pasteur SA
  • Romark Laboratories LC
  • Park Active Molecules
  • Novavax Inc
  • Mucosis BV
  • MedImmune LLC
  • Medicago Inc
  • Kineta Inc
  • Inovio Pharmaceuticals Inc
  • Green Cross Corp
  • GlaxoSmithKline Plc
  • Fujifilm Holdings Corporation
  • Daiichi Sankyo Company Ltd
  • ContraFect Corp
  • Cadila Healthcare Ltd
  • BioCryst Pharmaceuticals Inc
  • Aphios Corp
  • Amarillo Biosciences Inc
  • Altravax Inc
  • Adimmune Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenzavirus B Infection Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Influenzavirus B Infection Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Influenzavirus B Infection Drug Market by Type
  6. 1.3.1 KIN-1400
  7. 1.3.2 GC-3106A
  8. 1.3.3 CF-403
  9. 1.3.4 APP-309
  10. 1.3.5 Others
  11. 1.4 Global Influenzavirus B Infection Drug Market Size by Type
  12. 1.4.1 Global Influenzavirus B Infection Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Influenzavirus B Infection Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Influenzavirus B Infection Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Influenzavirus B Infection Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Influenzavirus B Infection Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Influenzavirus B Infection Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Influenzavirus B Infection Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Influenzavirus B Infection Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Influenzavirus B Infection Drug Industry Trends
  2. 2.2 Influenzavirus B Infection Drug Industry Drivers
  3. 2.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
  4. 2.4 Influenzavirus B Infection Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Influenzavirus B Infection Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Influenzavirus B Infection Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Influenzavirus B Infection Drug Price (2021-2026)
  4. 3.4 Global Influenzavirus B Infection Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenzavirus B Infection Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Influenzavirus B Infection Drug Company, Product Type & Application
  7. 3.7 Global Influenzavirus B Infection Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenzavirus B Infection Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenzavirus B Infection Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenzavirus B Infection Drug Tier 1, Tier 2, and Tier 3
4 Influenzavirus B Infection Drug Regional Status and Outlook
  1. 4.1 Global Influenzavirus B Infection Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Influenzavirus B Infection Drug Historic Market Size by Region
  3. 4.2.1 Global Influenzavirus B Infection Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Influenzavirus B Infection Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Influenzavirus B Infection Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Influenzavirus B Infection Drug Forecasted Market Size by Region
  7. 4.3.1 Global Influenzavirus B Infection Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Influenzavirus B Infection Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Influenzavirus B Infection Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Influenzavirus B Infection Drug by Application
  1. 5.1 Influenzavirus B Infection Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Influenzavirus B Infection Drug Market Size by Application
  6. 5.2.1 Global Influenzavirus B Infection Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Influenzavirus B Infection Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Influenzavirus B Infection Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Influenzavirus B Infection Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Influenzavirus B Infection Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Influenzavirus B Infection Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Influenzavirus B Infection Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Influenzavirus B Infection Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 AbbVie Inc
  8. 6.2.1 AbbVie Inc Company Information
  9. 6.2.2 AbbVie Inc Business Overview
  10. 6.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
  12. 6.2.5 AbbVie Inc Recent Developments
  13. 6.3 Vectura Group Plc
  14. 6.3.1 Vectura Group Plc Company Information
  15. 6.3.2 Vectura Group Plc Business Overview
  16. 6.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
  18. 6.3.5 Vectura Group Plc Recent Developments
  19. 6.4 Vaxart Inc
  20. 6.4.1 Vaxart Inc Company Information
  21. 6.4.2 Vaxart Inc Business Overview
  22. 6.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
  24. 6.4.5 Vaxart Inc Recent Developments
  25. 6.5 TSRL Inc
  26. 6.5.1 TSRL Inc Company Information
  27. 6.5.2 TSRL Inc Business Overview
  28. 6.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
  30. 6.5.5 TSRL Inc Recent Developments
  31. 6.6 SK Chemicals Co Ltd
  32. 6.6.1 SK Chemicals Co Ltd Company Information
  33. 6.6.2 SK Chemicals Co Ltd Business Overview
  34. 6.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
  36. 6.6.5 SK Chemicals Co Ltd Recent Developments
  37. 6.7 Shionogi & Co Ltd
  38. 6.7.1 Shionogi & Co Ltd Company Information
  39. 6.7.2 Shionogi & Co Ltd Business Overview
  40. 6.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
  42. 6.7.5 Shionogi & Co Ltd Recent Developments
  43. 6.8 Sanofi Pasteur SA
  44. 6.8.1 Sanofi Pasteur SA Company Information
  45. 6.8.2 Sanofi Pasteur SA Business Overview
  46. 6.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
  48. 6.8.5 Sanofi Pasteur SA Recent Developments
  49. 6.9 Romark Laboratories LC
  50. 6.9.1 Romark Laboratories LC Company Information
  51. 6.9.2 Romark Laboratories LC Business Overview
  52. 6.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
  54. 6.9.5 Romark Laboratories LC Recent Developments
  55. 6.10 Park Active Molecules
  56. 6.10.1 Park Active Molecules Company Information
  57. 6.10.2 Park Active Molecules Business Overview
  58. 6.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
  60. 6.10.5 Park Active Molecules Recent Developments
  61. 6.11 Novavax Inc
  62. 6.11.1 Novavax Inc Company Information
  63. 6.11.2 Novavax Inc Business Overview
  64. 6.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
  66. 6.11.5 Novavax Inc Recent Developments
  67. 6.12 Mucosis BV
  68. 6.12.1 Mucosis BV Company Information
  69. 6.12.2 Mucosis BV Business Overview
  70. 6.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
  72. 6.12.5 Mucosis BV Recent Developments
  73. 6.13 MedImmune LLC
  74. 6.13.1 MedImmune LLC Company Information
  75. 6.13.2 MedImmune LLC Business Overview
  76. 6.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
  78. 6.13.5 MedImmune LLC Recent Developments
  79. 6.14 Medicago Inc
  80. 6.14.1 Medicago Inc Company Information
  81. 6.14.2 Medicago Inc Business Overview
  82. 6.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
  84. 6.14.5 Medicago Inc Recent Developments
  85. 6.15 Kineta Inc
  86. 6.15.1 Kineta Inc Company Information
  87. 6.15.2 Kineta Inc Business Overview
  88. 6.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
  90. 6.15.5 Kineta Inc Recent Developments
  91. 6.16 Inovio Pharmaceuticals Inc
  92. 6.16.1 Inovio Pharmaceuticals Inc Company Information
  93. 6.16.2 Inovio Pharmaceuticals Inc Business Overview
  94. 6.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  96. 6.16.5 Inovio Pharmaceuticals Inc Recent Developments
  97. 6.17 Green Cross Corp
  98. 6.17.1 Green Cross Corp Company Information
  99. 6.17.2 Green Cross Corp Business Overview
  100. 6.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
  102. 6.17.5 Green Cross Corp Recent Developments
  103. 6.18 GlaxoSmithKline Plc
  104. 6.18.1 GlaxoSmithKline Plc Company Information
  105. 6.18.2 GlaxoSmithKline Plc Business Overview
  106. 6.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
  108. 6.18.5 GlaxoSmithKline Plc Recent Developments
  109. 6.19 Fujifilm Holdings Corporation
  110. 6.19.1 Fujifilm Holdings Corporation Company Information
  111. 6.19.2 Fujifilm Holdings Corporation Business Overview
  112. 6.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
  114. 6.19.5 Fujifilm Holdings Corporation Recent Developments
  115. 6.20 Daiichi Sankyo Company Ltd
  116. 6.20.1 Daiichi Sankyo Company Ltd Company Information
  117. 6.20.2 Daiichi Sankyo Company Ltd Business Overview
  118. 6.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
  120. 6.20.5 Daiichi Sankyo Company Ltd Recent Developments
  121. 6.21 ContraFect Corp
  122. 6.21.1 ContraFect Corp Company Information
  123. 6.21.2 ContraFect Corp Business Overview
  124. 6.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
  126. 6.21.5 ContraFect Corp Recent Developments
  127. 6.22 Cadila Healthcare Ltd
  128. 6.22.1 Cadila Healthcare Ltd Company Information
  129. 6.22.2 Cadila Healthcare Ltd Business Overview
  130. 6.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
  132. 6.22.5 Cadila Healthcare Ltd Recent Developments
  133. 6.23 BioCryst Pharmaceuticals Inc
  134. 6.23.1 BioCryst Pharmaceuticals Inc Company Information
  135. 6.23.2 BioCryst Pharmaceuticals Inc Business Overview
  136. 6.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  138. 6.23.5 BioCryst Pharmaceuticals Inc Recent Developments
  139. 6.24 Aphios Corp
  140. 6.24.1 Aphios Corp Company Information
  141. 6.24.2 Aphios Corp Business Overview
  142. 6.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
  144. 6.24.5 Aphios Corp Recent Developments
  145. 6.25 Amarillo Biosciences Inc
  146. 6.25.1 Amarillo Biosciences Inc Company Information
  147. 6.25.2 Amarillo Biosciences Inc Business Overview
  148. 6.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
  150. 6.25.5 Amarillo Biosciences Inc Recent Developments
  151. 6.26 Altravax Inc
  152. 6.26.1 Altravax Inc Company Information
  153. 6.26.2 Altravax Inc Business Overview
  154. 6.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
  156. 6.26.5 Altravax Inc Recent Developments
  157. 6.27 Adimmune Corp
  158. 6.27.1 Adimmune Corp Company Information
  159. 6.27.2 Adimmune Corp Business Overview
  160. 6.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
  162. 6.27.5 Adimmune Corp Recent Developments
7 North America by Country
  1. 7.1 North America Influenzavirus B Infection Drug Sales by Country
  2. 7.1.1 North America Influenzavirus B Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Influenzavirus B Infection Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Influenzavirus B Infection Drug Market Size by Country
  6. 7.2.1 North America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Influenzavirus B Infection Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Influenzavirus B Infection Drug Sales by Country
  2. 8.1.1 Europe Influenzavirus B Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Influenzavirus B Infection Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Influenzavirus B Infection Drug Market Size by Country
  6. 8.2.1 Europe Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Influenzavirus B Infection Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Influenzavirus B Infection Drug Sales by Country
  2. 9.1.1 Asia-Pacific Influenzavirus B Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Influenzavirus B Infection Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Influenzavirus B Infection Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Influenzavirus B Infection Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Influenzavirus B Infection Drug Sales by Country
  2. 10.1.1 South America Influenzavirus B Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Influenzavirus B Infection Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Influenzavirus B Infection Drug Market Size by Country
  6. 10.2.1 South America Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Influenzavirus B Infection Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Country
  2. 11.1.1 Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Influenzavirus B Infection Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Influenzavirus B Infection Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Influenzavirus B Infection Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Influenzavirus B Infection Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Influenzavirus B Infection Drug Value Chain Analysis
  2. 12.1.1 Influenzavirus B Infection Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Influenzavirus B Infection Drug Production Mode & Process
  7. 12.2 Influenzavirus B Infection Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Influenzavirus B Infection Drug Distributors
  10. 12.2.3 Influenzavirus B Infection Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst